Journal of pain and symptom management
-
J Pain Symptom Manage · Sep 2019
Perception of multiple sclerosis impact and treatment efficacy beliefs: mediating effect of patient's illness and self-appraisals.
Patients with multiple sclerosis (MS) experience many negative, seriously aggravating disease symptoms, and hence, research studies are utmost required to improve their coping with symptoms. Our research is an attempt to show ways to increase participation of patients with MS in the treatment and treatment planning process, as well as in managing the symptoms of the disease. ⋯ Our results indicate that worse perception of physical condition in patients with MS is associated with more negative treatment efficacy beliefs, and that this association is mediated by self-efficacy and illness perception. To inhibit the increase of negative treatment efficacy beliefs, health care specialists can work on improving self-efficacy and illness appraisals.
-
Many of our experiences in hospice and palliative care medicine are challenging. We support dying patients and their families as they struggle with the transition from life to death and continue to support those in mourning. Many times, in America, it is difficult to even appreciate a glimmer of spiritual grace as our patients die. ⋯ It spanned and interconnected many eclectic faith traditions, theologies, and philosophies, including Taoism, Greek mythology, distributed cognition, mathematics, and Tibetan Buddhism. It resonated strongly with Zen and Christian mysticism. Some of Bruno's being and transformation to nonbeing was obvious; some of it was inscrutable.
-
J Pain Symptom Manage · Sep 2019
Clinical TrialCebranopadol, a novel first-in-class analgesic drug candidate: first experience with cancer-related pain for up to 26 weeks.
Pain is one of the most prevalent symptoms associated with cancer. Strong opioids are commonly used in the analgesic management of the disease, but carry the risk of severe side effects. Cebranopadol is a first-in-class drug candidate, combining nociceptin/orphanin FQ peptide and opioid peptide receptor agonism. For cancer patients, frequently experiencing multimorbidities and often exposed to polypharmacy, cebranopadol is easy to handle given its once-daily dosing, the small tablet size that enables swallowing, and the option to flexibly titrate to an effective dose. ⋯ Our data suggest that cebranopadol was safe and well tolerated when administered for up to 26 weeks in patients with chronic cancer-related pain who were previously treated with cebranopadol or morphine prolonged release.
-
J Pain Symptom Manage · Sep 2019
Integration of Palliative Care and Infection Management at End-of-Life in US Nursing Homes.
Infections in nursing home (NH) residents are often terminal illnesses. Integration of palliative care (PC) and infection management (IM) is a new concept that can help reduce burdensome treatments and improve quality of care for NH residents at the end of life. ⋯ Integration is a distinct concept that is associated with, but different from, PC and IM. Results serve as a baseline assessment of integration in NHs. Continued refinement of the integration instrument is recommended, as is studying if higher integration leads to better resident outcomes.